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Acute myeloid leukemia (AML) has poor prognosis due to various mutations, e.g., in the FLT3 gene. Therefore, it is important to
identify pathways regulated by the activated Flt3 receptor for the discovery of new therapeutic targets. The Myc network of
oncogenes and tumor suppressor genes is involved in mechanisms regulating proliferation and survival of cells, including that of
the hematopoietic system. In this study, we evaluated the expression of the Myc oncogenes and Mxd antagonists in
hematopoietic stem cell and myeloid progenitor populations in the Flt3-ITD-knockin myeloproliferative mouse model. Our data
shows that the expression of Myc network genes is changed in Flt3-ITD mice compared with the wild type. Mycn is increased in
multipotent progenitors and in the pre-GM compartment of myeloid progenitors in the ITD mice while the expression of
several genes in the tumor suppressor Mxd family, including Mxd1, Mxd2, and Mxd4, is concomitantly downregulated, as well
as the expression of the Mxd-related gene Mnt and the transcriptional activator Miz-1. LSKCD150+CD48− hematopoietic long-
term stem cells are decreased in the Flt3-ITD cells while multipotent progenitors are increased. Of note, PKC412-mediated
inhibition of Flt3-ITD signaling results in downregulation of cMyc and upregulation of the Myc antagonists Mxd1, Mxd2, and
Mxd4. Our data provides new mechanistic insights into downstream alterations upon aberrant Flt3 signaling and rationale for
combination therapies for tyrosine kinase inhibitors with Myc antagonists in treating AML.
1. Introduction
Acute myeloid leukemia (AML), despite aggressive treatment
regimes, has a poor prognosis, and cure is diﬃcult to attain.
Mutations in the tyrosine kinase receptor Flt3, including
internal tandem duplication (ITD) mutations and tyrosine
kinase domain (TKD) mutations, are the most common
changes in AML, which constitutively activate the Flt3 recep-
tor [1]. Flt3 regulates growth and survival of myeloid progen-
itor cells; therefore, mutations in FLT3 eﬀectively abrogate
growth-regulating controls [2]. Interestingly, mutations in
FLT3 are correlated with shorter progression-free survival
and overall survival [3, 4].
Treatment strategies aimed at inhibiting the activated
Flt3-ITD receptor have been evaluated in clinical trials;
however, the use of Flt3-ITD inhibitors as single agents
resulted in poor clinical outcome due to emergence of
drug-resistant cells [5]. This underscores the need to develop
combination treatment strategies [6]. Therefore, it is impor-
tant to identify pathways regulated by the activated Flt3
receptor for the development of new treatment targets. Sev-
eral pathways have been implicated downstream of the
mutated Flt3 receptor in leukemias, including the Wnt path-
way and the JAK/STAT pathway [7, 8].
Interestingly, the MYC oncogenes have been implicated
downstream of Flt3-ITD signaling [9]. The MYC family
genes, including MYC, MYCN, and MYCL1, are proto-
oncogenes and known to be overexpressed or mutated in a
plethora of diﬀerent tumors, including that of the hemato-
poietic system [10, 11]. The MYC proteins function as
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transcription factors and bind to speciﬁc E-box DNA
sequences, in promoters of target genes by heterodimerizing
with their partner MAX [12]. However, Myc also regulates
genes independent of DNA binding via Miz-1 protein [13].
Intriguingly, bone marrow-speciﬁc overexpression of Mycn
results in rapid development of acute myeloid leukemia
[14]. Furthermore, Myc has also been shown to induce mye-
loid myeloproliferative disease, even though mutations in
myeloid neoplasias are not common [15]. The Mxd family
of proteins also heterodimerizes with Max and binds to the
common E-box sequences and generally works in an antago-
nistic way towards Myc [12].
Importantly, several reports have implicated Myc as a
downstream target of Flt3-ITD signaling. To this end, it
was shown that Flt3-ITD regulates cMyc via Wnt signaling
[8]. Additionally, Flt3-ITD inhibits Foxo3a [16], which in
turn suppresses the Myc antagonist Mxi-1 (Mxd2) to
increase Myc activity [17]. Interestingly, studies of Myc
function in hematopoietic stem cells have implicated Myc
in pushing the HSCs out of the niche and into a prolifer-
ative progenitor state [18]. Given that both Flt3 and Myc
regulate HSCs’ self-renewal and diﬀerentiation, evaluating
the interplay between Flt3-ITD signaling and Myc mole-
cules may represent therapeutic targets for AML therapy.
In this study, we investigated the Myc network genes in
diﬀerent subpopulations in the bone marrow, including mye-
loid progenitors and stem cell populations, in the Flt3-ITD
myeloproliferative mouse model [19]. Here, we report that
the expression of the Myc network genes is changed in the
Flt3-ITD mouse model, mainly with upregulation of the
Myc genes and concomitant downregulation of the Myc
antagonists, the Mxd genes, in diﬀerent hematopoietic stem
and progenitor cell subpopulations, as well as downregula-
tion of the Mxd-related gene Mnt and the transcriptional
activator Miz-1. Moreover, PKC412-mediated inhibition of
Flt3-ITD signaling results in downregulation of c-Myc and
upregulation of the Myc antagonists Mxd1, Mxd2/Mxi1,
and Mxd4.
2. Materials and Methods
2.1. Cell Culture and PKC412 Inhibitor. MV4-11 cells were
cultured in IMDM medium (Sigma-Aldrich) supplemented
with 20% FCS, 1% L-glutamine, and 1% penicillin/strepto-
mycin. Cells were constantly maintained at 37°C in 5%
CO2. The Flt3-ITD phosphokinase inhibitor was added to
cell cultures of MV4-11 cells in 2 diﬀerent concentrations
for 15 minutes before the cells were harvested for mRNA
extraction (0.1mM and 1mM) (LC Laboratories, Woburn,
MA, USA).
2.2. Mice. Flt3-ITD-knockin mice on C57BL/6 background
were previously described [19]. WT (Flt3+/+) C57BL/6 litter-
mate mice were used as WT controls. All experiments were
approved by the Ethical Committee at Lund University.
2.3. Fluorescent Antibodies and Immunomagnetic Beads Used
for FACS Analysis and Sorting. Antibodies used for cell sur-
face staining were as follows: CD11b/Mac1 (M1/70), CD4
(H129.19), CD8a (53–6.7), B220/CD45 (RA3–6B2), CD5
(Ly1), Ter119 (Ter-1119), Gr1/Ly6G and Ly6C (RB6–8C5),
CD19 (ID3), CD41/Itga2b (MWReg30), and CD135/Flt3
(A2F10.1) (104) (BD Biosciences Pharmingen) and NK1.1
(PK136), Sca1 (D7), CD117/c-Kit (2B8), CD16/32 (93), and
CD105/Eng (MJ7/18) (eBioscience). Biotinylated antibodies
were visualized with streptavidin-QD655 (Invitrogen) or
streptavidin-tricolor (Invitrogen), and puriﬁed lineage anti-
bodies were visualized with polyclonal goat anti-rat tricolor
(Invitrogen) or polyclonal goat anti-rat-QD605 (Invitrogen).
MACS column enrichment of c-Kit+ cells was done using
anti-CD117 immunomagnetic beads (Miltenyi Biotec) as
previously described [20].
2.4. Flow Cytometric Analysis. Hematopoietic stem and
progenitor cells were analyzed as previously described.
[21–23]. Brieﬂy, bone marrow (BM) cells were stained
with a cocktail of puriﬁed rat antibodies against lineage
markers B220, CD4, CD5, CD8α, CD11b, Gr1, and Ter119.
Lineage+ cells were visualized with a goat anti-rat-QD605
staining, followed by c-Kit enrichment for sorting analyses.
Thereafter, hematopoietic stem/progenitor cells were
deﬁned as Lin−Sca1+c-Kit+ (LSK) cells, pre-granulocyte-
monocyte progenitors (pre-GMPs: Lin−c−Kit+Sca1− [LSK−]
CD41−CD16/32low/−CD150−CD105low/−), granulocyte-monocyte
progenitors (GMPs: LKS−CD16/32hiCD150−), and multipotent
progenitors (MPPs: Lin−Sca1+ c-Kit+CD150−CD105low/−).
Propidium iodide (Invitrogen) was used to exclude dead
cells. Cell acquisition and analysis were performed on a
4-laser LSRII (BD Biosciences) using FlowJo version 8.8
software (TreeStar). Cell sorting was done on a FACSAria
(BD Biosciences).
2.5. Quantitative Real-Time PCR. For analyzing gene expres-
sion in myeloid progenitors (pre-GM, GMPs) as well as in
hematopoietic stem cells and multipotent progenitors
(MPPs), cells from these populations were FACSAria-sorted
directly into 75μl of buﬀer RLT and frozen at −80°C. Total
RNA extraction and DNase treatment were performed with
the RNeasy Micro kit (Qiagen Inc., California) according to
the manufacturer’s instructions for samples containing ≤105
cells. Eluted RNA samples were reverse-transcribed using
the SuperScript II Reverse Transcriptase Kit including
random hexamers (Invitrogen) according to the protocol
supplied by the manufacturer. For gene expression in LT-
HSCs as well as in MPPs using the Slam marker staining
(including CD150 and CD48), the CelluLyser™ protocol
(TaTaa, Gothenburg, Sweden) was used according to the
manufacturer’s protocol. Shortly, cells were FACSAria-
sorted into 5 5∝ l lysis buﬀer where RNA was directly
reverse-transcribed using the Transcriptor First-Strand
cDNA synthesis kit (Roche). Q-PCR reactions with the
diluted cDNA samples were analyzed with TaqMan gene
expression assays (ABI, USA) according to the manufac-
turer’s protocol. TaqMan Assays-on-Demand probes used
are described in the Supplemental Experimental Proce-
dures. All experiments were performed in triplicate and
from at least two diﬀerent sorts, and diﬀerences in cDNA
input were compensated by normalizing against β-actin or
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HPRT expression levels. The fold induction ratio was calcu-
lated by the Pfaﬄ equation:
ratio =
Etarget ΔCt target control − sample
Eref ΔCt ref control − sample
1
Statistical analysis was performed with two-tailed unpaired
Student’s t-test on log-converted values (∗p < 0 05, ∗∗p < 0 01).
3. Results
3.1.Myeloid Progenitor andHematopoietic StemCell Populations
Are Changed in Flt3-ITD Mice. To evaluate the gene expression
of theMYC network genes in the bonemarrow of Flt3-ITDmice
compared with wild-type (WT) mice, hematopoietic stem cell
and myeloid progenitor (MPP) subpopulations were identiﬁed
by staining for surface markers, analyzed by ﬂuorescence-
activated cell sorting (FACS), and subsequently sorted. Initially,
myeloid progenitors including pre-GM and granulocytic
myeloid progenitors (GMPs), as well as Lin−Sca-1+Kit+
(LSK) cells, within which hematopoietic stem cells reside,
were sorted using a staining procedure including endoglin
and the SLAM receptor CD150, as described previously [23].
The Flt3-ITD mouse has a myeloproliferative disease
with expanded myeloid populations [19]. Consistently, we
observed that myeloid progenitors (MPs/LK; Lin−Sca-1−Kit+
cells) in Flt3-ITD mice are increased to 69.5% in comparison
with 54.9% MPs in WT mice (Figure 1(a)). Moreover, we
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Figure 1: Myeloid progenitor and hematopoietic stem cell populations are changed in Flt3-ITD mice. Analysis of hematopoietic stem cell
(HSC) and multipotent progenitor (MPP) subpopulations within the Lin−Sca-1+Kit+ (LSK) population, as well as myeloid progenitors
including pre-GM and granulocytic myeloid progenitors (GMPs), in the bone marrow of Flt3-ITD and wild-type (WT) mice, was
performed using a staining procedure including endoglin and the SLAM receptor CD150.
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observed that the relative distribution of subpopulations
within theMP compartment was altered as well. Importantly,
progenitors of the granulocytic/monocytic pathway (pre-GM
and GMPs) were increased in Flt3-ITD mice in comparison
toWTmice, asweobserved that pre-GMswere increased from
39% inWTto65% inFlt3-ITDmice andGMPswere increased
from 41% inWT to 86% in ITDmice (Figure 1(a)). Consistent
with our previous data [24], the progenitors of themegakaryo-
cytic and erythroid pathway were diminished (Figure 1(a)).
The expression of Flt3 is altered or diminished due to the
ITD mutation; therefore, staining to identify HSC subpop-
ulations by utilizing the expression of the Flt3 receptor is
not feasible. Here, we identiﬁed long-term (LT-) HSCs as
CD150+CD105+ utilizing CD150 and endoglin (CD105),
while MPPs were identiﬁed as CD150−/CD105+. Intrigu-
ingly, we observed a decrease in LT-HSCs in favor of MPPs
in the ITD mice (Figure 1(b)). Collectively, the above data
set indicates that ITD mutation in Flt3 results in the expan-
sion of the pre-GM, GMP, and MPP compartments.
3.2. Myeloid and Multipotent Progenitors Have Altered Myc
Network Genes in Flt3-ITD Mice. Next, we evaluated the
expression of the Myc network genes including cMyc and
Mycn, as well as the Mxd family of Myc antagonists (Mxd1,
Mxd2/Mxi1, Mxd3, and Mxd4), in stem and progenitor
subpopulations in mice with the Flt3-ITD mutation and lit-
termate WT controls by quantitative real-time PCR (Q-RT-
PCR) (Figure 2). The mRNA of the cMyc gene was increased
in Flt3-ITDMPPs (1.9-fold induction), as well as in Flt3-ITD
GMPs (2.83-fold induction). Of note, the Mycn expression
was increased in all the populations investigated in Flt3-
ITD mice, except for GMPs where the expression of Mycn
was turned oﬀ. Mycn was most prominently upregulated in
MPPs and pre-GM cells (4.04- and 10.96-fold induction,
respectively). Furthermore, analysis of the expression of the
Myc antagonists, theMad family genes, showed downregula-
tion ofMxd1 in LSK cells (0.62-fold reduction), MPPs (0.69-
fold reduction), and MPs (0.52-fold reduction). Mxd2/Mxi1
was downregulated in LSK (0.77-fold reduction) and MP
(0.41-fold reduction) cells and Mxd4 in MPs (0.68-fold
reduction). Additionally,Mxd2/Mxi1 andMxd3 were upreg-
ulated in MPPs. The MNT gene, an MXD family-related
gene, which is coexpressed with Myc in proliferating cells
and functions as a repressor of Myc target genes [25] was
downregulated (0.36-fold reduction) in myeloid progenitors
(MPs) in Flt3-ITD mice. Similarly, the MIZ-1 gene, a
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Figure 2: Myeloid and multipotent progenitors have altered Myc network genes in Flt3-ITDmice. The expression of Myc network genes was
carried out with reverse transcription quantitative PCR (RT-Q-PCR) in sorted subpopulations of murine hematopoietic stem and progenitor
cells. Fold induction was calculated as a ratio of Flt3-ITD :WT samples. Statistical analysis was performed with Student’s t-test on log-
converted values (∗p < 0 05). Signiﬁcance was shown in many of the described altered expression levels; however, some changes showed
low p values but did not quite reach statistically signiﬁcance due to variances in the expression levels.
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transcriptional activator which is involved in upregulating
growth-repressing genes such as p21, was downregulated
in LSK cells (0.58-fold reduction) and MPs (0.51-fold
reduction). Max, the Myc- and Mxd-interacting partner,
was signiﬁcantly increased in MPPs (1.75-fold induction)
and signiﬁcantly decreased in MPs (0.48-fold reduction)
(data not shown). Collectively, these data indicate that
the ITD mutation in Flt3 results in the alteration of Myc
network genes.
3.3. Hematopoietic Stem Cells in Flt3-ITD Mice Have Altered
Myc Network Expression. Next, we subdivided the hema-
topoietic stem cell compartment into long-term HSCs
(LT-HSCs) and MPPs, utilizing the SLAM receptor stain-
ing with CD150 and CD48 [22], and cells were sorted by
ﬂow cytometry for subsequent gene expression analysis. Of
note, the LT-HSCs (LSKCD150+CD48−) were decreased in
the Flt3-ITD cells, as described previously [26], and the
MPPs were increased. Intriguingly, MPPs expressed higher
levels of CD48 (Figure 3).
Expression of the Myc network genes was evaluated in
LSK, LT-HSC (CD150+CD48−), MPP (CD150−CD48+), and
MP cells. Intriguingly, the expression of the cMyc gene did
not change in LSK, LT-HSC, MPP, and MP cells as identiﬁed
in the SLAM receptor-based staining in contrast to the
staining including the endoglin marker (Figures 4 and 1).
Conversely, the Mycn mRNA was increased in MPP cells
(2.98-fold induction) (Figure 4), comparative with the
results from the analysis in the endoglin/CD150 staining
protocol (Figure 2). However, the results in this staining
did not quite reach signiﬁcant values due to variations.
Importantly, Mxd1 showed a signiﬁcant decrease in
expression in LT-HSCs (0.63-fold reduction), as well as
in MPPs (0.62-fold reduction) and the LSK compartment
(0.64-fold reduction), which, however, did not reach sig-
niﬁcant levels (Figure 4). Of note, Mxd2/Mxi1 and Mxd4
were signiﬁcantly decreased in the LSK compartment;
however, their expression did not change in LT-HSCs,
MPPs, and MPs. Conversely, Mxd3 did not change signif-
icantly in any of the subpopulations (Figure 4).
3.4. Small Molecule Inhibitor, PKC412, Modulates the
Expression of Myc Network Genes in Human MV4-11 Cells.
PKC412 is an inhibitor of FLT3 autophosphorylation,
thereby inhibiting downstream signaling [27]. It has shown
to inhibit growth of primary Flt3-ITD mutant blasts [28].
To investigate whether Flt3-ITD inhibition exerts antileu-
kemic activity via modulation of the Myc network, we
treated the human Flt3-ITD mutated leukemia cell line,
MV4-11, with PKC412 at two diﬀerent concentrations
(0.1mM and 1mM) and analyzed the expression of Myc
network genes. Of note, PKC412 reduced cMyc expression
to the same extent at both concentrations. Conversely, the
expression of the Myc antagonists Mxd1 and Mxd2 was
increased in a dose-dependent manner in MV4-11 cells
treated with PKC412 (Figure 5), as well as the expression
of Mxd4, but to a lesser extent. Intriguingly, MV4-11 cells
do not express Mycn (Figure 5).
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4. Discussion
Currently, a rapid development of targeted therapies against
speciﬁcally overexpressed or mutated molecules in AML is
ongoing. Clinical trials against mutated molecules found in
AML, e.g., IDH1 and IDH2, have recently been initiated
[29]. Considering the risk of relapse with the current treat-
ment, it is important to identify pathways regulated by the
activated Flt3 receptor for the identiﬁcation of new treatment
targets. The Myc network of oncogenes and tumor suppres-
sors is often changed in a plethora of tumors. The overex-
pression of the MYC and MYCN oncogenes is mostly not
due to actual mutations in the genes, but their expression is
deregulated due to upstream activated pathways and mole-
cules [30]. However, there are exceptions to the rule, as
MYCN is ampliﬁed in neuroblastomas [31]. Myc and Mycn
overexpression has been shown to initiate myeloid and lym-
phoid neoplasms and could therefore be possible targets for
inhibiting leukemic cell proliferation and viability. The Mxd
network of tumor suppressors has been shown to be down-
regulated or deleted in diﬀerent tumor types including pros-
tate adenocarcinoma [32]. In this study, we have analyzed the
possible role of the Myc network in Flt3-ITD-induced myelo-
proliferative disease. Flt3-ITD is one of the most common
mutations in AML and is correlated with poor prognosis.
Strategies of inhibiting the overactivated Flt3-ITD tyrosine
kinase or pathways downstream of this receptor would there-
fore be of interest in treating AML patients with this muta-
tion. Eﬀorts with Flt3-ITD inhibitors to treat AML are
ongoing. However, results have shown that the Flt3-ITD
inhibitor should be used in combination with other treat-
ments to avoid the development of drug resistance.
Herein, we report that myeloid progenitors (MPs) are
increased in adult Flt-3ITD mice, which is consistent with
other reports. Intriguingly, fetal Flt3-ITDmice have a normal
MP compartment and are protected from leukemic trans-
formation [33]. Similarly, LT-HSCs (LSKCD150+48−) were
reported to be present in normal numbers in Flt3-ITD
fetal livers before the onset of myeloproliferative disease.
However, we here show that LT-HSCs decrease in favor
of MPPs in Flt3-ITD mice which has developed a myelo-
proliferative disease, which has also been shown in other
reports ([34, 35, 26]). Evidence has shown that the eﬀect
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Figure 4: Hematopoietic stem cells in Flt3-ITDmice have altered Myc network expression. The expression of Myc network genes was carried
out with reverse transcription quantitative PCR (RT-Q-PCR) in hematopoietic stem cells. Fold induction was calculated as a ratio of
Flt3-ITD :WT samples. Statistical analysis was performed with Student’s t-test on log-converted values (∗p < 0 05, ∗∗p < 0 01).
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Figure 5: Small molecule inhibitor, PKC412, modulates the
expression of Myc network genes in human MV4-11 cells. The
human Flt3-ITD mutated leukemia cell line, MV4-11, was treated
with the Flt3-inhibitor PKC412 at two diﬀerent concentrations
(0.1mM and 1mM) for 15 minutes. Expression analysis of the Myc
network genes was carried out with RT-Q-PCR. ND: not detected.
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of Flt3-ITD on LT-HSC homeostasis is cell autonomous
[26]. Changes in the expression of the Myc network genes
downstream of Flt3-ITD could therefore be responsible for
an expansion of leukemic multipotent progenitors. Of
note, STAT3 is upregulated in Flt3-ITD MPPs [34]. More-
over, in adult progenitors, Flt3-ITD induces self-renewal in
a STAT5-dependent manner [36]. Interestingly, lineage-
speciﬁc STAT5 activation in hematopoietic progenitor cells
predicts the FLT3+-mediated leukemic phenotype in mice
[37], and the STAT signaling pathway has been reported
to increase Myc activity. These data highlight the involve-
ment of STAT signaling in connection with the Myc net-
work in aberrant hematopoietic stem and progenitor cell
populations in Flt3-ITD, which is thus also a potential
therapeutic target in Flt3-ITD leukemia.
We found that the Myc network of oncogenes and tumor
suppressors is changed in Flt3-ITD myeloproliferative mice
compared with wild-type mice. Generally, the Myc gene
expression was increased, and the expression of the Myc
antagonists, mainly Mxd1, Mxd2/Mxi1, Mxd4, Mnt, and
Miz-1, was decreased. Myc has been shown to be involved
in displacing quiescent hematopoietic stem cells from their
niche to more proliferative progenitor cells [38]. This can
be correlated with our results showing the change in hemato-
poietic stem and progenitor cell subpopulation distribution,
where the long-term hematopoietic stem cells are decreased
in Flt3-ITD mice and the multipotent progenitors increased.
Our data shows that cMyc was increased in Flt3-ITD multi-
potent progenitors (MPPs) as was Mycn in LSK, MPP, and
pre-GM cells. Importantly, c-MYC has been reported to
induce the expression of the deubiquitinase USP22, which
in turn reduced ubiquitination and enhanced the stability
of SIRT1 in CD34+ Flt3-ITD cells. Of note, inhibition of
SIRT1 expression or activity reduced the growth of Flt3-
ITD AML [39]. Additionally, c-MYC generates repair errors
by regulating transcriptional activation and expression of the
alternative nonhomologous end-joining pathway resulting in
aberrant DNA repair in Flt3-ITD leukemia [40]. Further,
N-Myc overexpression mechanistically results in the hyper-
proliferation of myeloid cells by decreasing transforming
growth factor β signaling and increasing c-Jun-NH2-kinase
signaling to cause AML [14]. Collectively, these data
underscore the importance of inhibition of the Myc mole-
cules in treating Flt3-ITD mutated AML. Furthermore, we
observed the downregulation of Mxd family genes, i.e.,
Mxd1, Mxd2/Mxi1, and Mxd4. Interestingly, Krüppel-like
factor 4 (KLF4) has been identiﬁed as an upstream tran-
scriptional regulator ofMxd1 andMyc in myeloid leukemias
[41]. Intriguingly, while SIRT1 was shown to regulate c-MYC
in Flt3-ITDmutated leukemia [39], it has been demonstrated
to regulate Mxd1 in malignant melanoma [42]. Similarly,
we found that Mnt and Miz-1 were also downregulated
in Flt3-ITD MPs. Of note, Miz-1 serves as a platform to
inhibit the expression of cell cycle regulators ([43, 44]).
Flt3-ITD mutated leukemic cells have enhanced activity
of Cdc25, which overrides the replication checkpoint lead-
ing to arrest in the S phase [45]. These ﬁndings could
point to the possibility that reduced levels of Miz-1 result
in enhanced activity of Cdc25 thereby deregulating the cell
cycle in Flt3-ITD leukemia. Given that compromised DNA
damage response and weakened cell cycle checkpoint pro-
mote the progression of AML, our data points to the
potential role of Myc and Miz-1 in regulating these path-
ways in Flt3-ITD leukemia.
As the phosphorylation status of FLT3 is associated
with its functional activity [46], the inhibition of FLT3
phosphorylation will aﬀect FLT3-dependent pathways such
as RAS/MAPK, JAK/STAT, and Wnt pathways [9]. Given
that Myc oncogenes are downstream eﬀectors of these
pathways and based on our results that Myc oncogenes
are altered upon ITD mutation in FLT3, we hypothesized
that modulation of FLT3 phosphorylation will result in
transcriptional reprogramming of the Myc network. Our
data showed that PKC412-mediated inhibition of FLT3
signaling increased Mxd1 and Mxd2 expression, as well
as the expression of Mxd4 and Mnt to a lesser degree,
while it reduced cMyc expression in Flt3-ITD AML cells.
During the course of preparation of this manuscript,
Zhang et al. reported that PKC412-induced Myc downreg-
ulation results in decreased telomerase reverse transcrip-
tase (hTERT) activity [47]. Additionally, inhibition of
cMyc has several therapeutic implications in solid tumors
and hematological malignancies. It has been reported that
cMyc inhibition overcomes radio- and chemotherapy resis-
tance in pediatric medulloblastoma [48]. Similarly, cMyc
inhibition has been shown to negatively impact lymphoma
growth [49] and overcome drug-resistant AML [33]. Fur-
thermore, cMyc inhibition prevents leukemia initiation in
mice and impairs the growth of relapsed and induction
failure pediatric T-ALL cells [50]. Our data showed that
selective inhibition of Flt3-ITD downstream signaling
induced c-Myc inhibition, which is consistent with a
recent report [47]. Furthermore, our data also shows that
Mnt and Miz-1 of the Mxd family are targets of Flt3-
ITD signaling pointing to the Myc network as a whole
being a target of activated Flt3-ITD. Additionally, our data
showed that nMyc expression is increased in LSK, MPP,
and pre-GM cells from Flt3-ITD mice. Reports supporting
the important role of the inhibition of the Mxd family of
tumor suppressors include studies showing that Mxd1
promotes cell cycle arrest and diﬀerentiation [30]; also,
several studies showed deletion of the 10q24-q25 chromo-
some, where the MXD2 gene is located in solid tumors
[51]. Furthermore, MXD2 is mutated in hematological
malignancies [52], as well as in solid tumors. Interestingly,
reintroduction of Mxd2 in glioblastoma cells deﬁcient in
Mxd2 results in reduced glioblastoma cell growth and clo-
nogenicity [53]. Our study points to the fact that alter-
ations in the Myc network by Flt3-ITD signaling are
involved in myeloid leukemogenesis and that PKC412-
mediated Flt3-ITD inhibition partly exerts its antileukemic
activity by aﬀecting the Myc/Max/Mxd network.
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